Juvenile dermatomyositis

Abstract

the subgroups of patients with JIA. The mean (SD) antibody levels in the children with JIA were significantly lower (175.5 (118.4) mIU/ ml) than those of the healthy subjects (317.08 (180.5) mIU/ml) There was no diVerence between the sexes in vaccine responsiveness. When the antibody levels between the two vaccination schedules were compared in healthy children, there was no statistical diVerence. However, there was a slightly higher, but statistically insignificant, response in JIA subjects vaccinated in group II than in those in group I. The vaccine responsiveness was not influenced either by methotrexate or prednisolone treatment. However, there was a negative correlation between prednisolone dose and anti-HBs titre (r=−0.23). Conclusion-Children with JIA responded adequately to hepatitis B vaccination, and this response was not negatively influenced by immunosuppressive treatment. The more appropriate vaccination schedule for children with JIA is the schedule given at 0, 1, and 6 months.

Fatores de risco associados à calcinose na dermatomiosite juvenil

“…[1][2][3] It is part of a heterogenous group of acquired muscle diseases, the idiopathic inflammatory myopathies, whose common denominator is the presence of weak muscles with inflammatory infiltrates. Characterization of this group of pathologies is based on its pattern of muscle involvement, the presence of associated clinical manifestations, histopathological findings, response to treatment and prognosis.…”

Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease

“…She was negative for antibody to ribonuclear protein, which is present in 36%-65% of patients who are anti-PL-12-positive 10 . VWF:Ag is often an indicator of a disease flare in IIM 13,14 , and our patient exhibited high vWF:Ag levels at presentation, persisting for 9 months. Her disease course was similar to those of adults with both anti-PL-12 and anti-Ro antibody, in whom ILD is difficult to control.…”

Calcinose na infância, um desafio terapêutico

“…A complicação mais comum da DMJ é a calcinose (12) . Esta costuma aparecer durante a fase de atividade da doença e, geralmente, está relacionada à doença cutânea grave, à vasculopatia importante, ao curso crônico e ao atraso no diagnóstico e tratamento (4) . O aparecimento da calcinose ocorre mais freqüentemente um a três anos após o início da doença, mas tem sido relatada até 20 anos após a instalação desta (13) .…”

“…A patogênese é desconhecida, mas parece envolver a ação de células inflamatórias, citocinas e proteínas da matriz mineralizada, como osteocalcina, entre outras (3) . Atraso no início do tratamento, vasculopatia e doença grave são fatores de risco para o aparecimento de calcinose nesses pacientes (4)(5)(6) . Muitas medicações têm sido utilizadas para tratar calcinose, algumas com sucesso em poucos relatos de caso.…”

“…Calcinose na Infância, um Desafio Terapêutico Calcinosis in Juvenile Dermatomyositis, A Therapeutic Challenge Tânia Caroline Monteiro de Castro (1) , Edson Yamashita (2) , Maria Teresa R. A. Terreri (3) , Claúdio Arnaldo Len (4) , Maria Odete Esteves Hilário (5) Os autores relatam e discutem o uso de algumas dessas medicações, como o alendronato, o diltiazen e a imunoglobulina endovenosa (IGEV) no tratamento da calcinose em dois pacientes com DMJ e fazem uma revisão da literatura das medicações mais utilizadas nesta que é a seqüela mais característica e a menos compreendida da DMJ.…”